Drug
Rebif
Rebif: highest development phase Post-Market, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rebif® NCT02064816 | Post-Market | Multiple Sclerosis, Relapsing-Remitting |
Latest
No recent events.
Follow Rebif on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.